RCS - Champions Oncology - Champions Oncology News Announcement
02/11/2023 13:45
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231102:nRSB2193Sa&default-theme=true RNS Number : 2193S Champions Oncology, Inc. 02 November 2023 Champions Oncology News Announcement Champions Oncology's European Research Operations Site Receives ISO-9001:2015 Accreditation and ATS Certification HACKENSACK, NJ / ACCESSWIRE / November 2, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, announced its European research operations site in Bresso, Italy, received ISO-9001:2015 laboratory accreditation from the Bureau Veritas S.p.A. and ATS certification from the Lombardy Region. These two achievements together continue to strengthen Champions Oncology's reputation as a global clinical specialty testing provider within Europe. These standards demonstrate that Champions is qualified to design assays, deliver analysis, and manage data effectively for clinical trials using flow cytometry or pathology techniques. Obtaining ISO-9001:2015 accreditation and ATS certification validates the quality of clinical testing services that Champions Oncology's European research team can provide and will enable specialty testing of clinical patient sample across all phases for our global biopharma partners in Europe. Ronnie Morris, CEO of Champions Oncology stated, "We are extremely proud of our talented scientists. With these achievements, we can continue to grow our customer base in Europe, while continuing to provide clinical expertise and fostering relationships with our existing clients." About Champions Oncology Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com (https://pr.report/JQ06hZSH) . Media Inquiries: Rachel Bunting, MS, MBA VP, Global Marketing 8474045394 Marketing@ChampionsOncology.com Website: www.championsoncology.com (https://pr.report/DIP1fGFy) Facebook: https://www.facebook.com/championsoncology/ (https://pr.report/fQzL6TRK) LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/ (https://pr.report/03Fyhwt7) Twitter: https://twitter.com/ChampionsOncol1 (https://pr.report/5JZVPw-z) Instagram: https://www.instagram.com/championsoncology/ (https://pr.report/mSh2IErL) SOURCE: Champions Oncology, Inc. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END NRAFLFVLLTLFIIV